These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25644460)

  • 1. A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.
    Blommestein HM; Franken MG; Uyl-de Groot CA
    Pharmacoeconomics; 2015 Jun; 33(6):551-60. PubMed ID: 25644460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.
    Blommestein HM; Issa DE; Pompen M; Ten Hoor G; Hogendoorn M; Joosten P; Zweegman S; Huijgens PC; Uyl-de Groot CA
    Eur J Haematol; 2014; 92(5):398-406. PubMed ID: 24400940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh.
    Teerawattananon Y; Tantivess S; Yamabhai I; Tritasavit N; Walker DG; Cohen JT; Neumann PJ
    Health Res Policy Syst; 2016 Dec; 14(1):86. PubMed ID: 27912780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands.
    Franken MG; van Gils CW; Gaultney JG; Delwel GO; Goettsch W; Huijgens PC; Steenhoek A; Punt CJ; Koopman M; Redekop WK; Uyl-de Groot CA
    Eur J Cancer; 2013 Jan; 49(1):8-16. PubMed ID: 22809557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences.
    de Groot S; van der Linden N; Franken MG; Blommestein HM; Leeneman B; van Rooijen E; Koos van der Hoeven JJ; Wouters MW; Westgeest HM; Uyl-de Groot CA
    Value Health; 2017 Apr; 20(4):627-636. PubMed ID: 28408005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
    Chabot I; Rocchi A
    Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.
    Baltussen R; Leidl R; Ament A
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):449-58. PubMed ID: 10662392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care.
    Uyl-de Groot CA
    Eur J Cancer; 2006 Nov; 42(17):2862-6. PubMed ID: 17008095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analyses using real-world data: an overview of the literature.
    Bowrin K; Briere JB; Levy P; Millier A; Clay E; Toumi M
    J Med Econ; 2019 Jun; 22(6):545-553. PubMed ID: 30816067
    [No Abstract]   [Full Text] [Related]  

  • 12. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
    Garrison LP; Veenstra DL
    Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year comprehensive medical management of degenerative lumbar spine disease (lumbar spondylolisthesis, stenosis, or disc herniation): a value analysis of cost, pain, disability, and quality of life: clinical article.
    Parker SL; Godil SS; Mendenhall SK; Zuckerman SL; Shau DN; McGirt MJ
    J Neurosurg Spine; 2014 Aug; 21(2):143-9. PubMed ID: 24785973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method for using real world data in breast cancer modeling.
    Pobiruchin M; Bochum S; Martens UM; Kieser M; Schramm W
    J Biomed Inform; 2016 Apr; 60():385-94. PubMed ID: 26854868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making cost assessments based on RCTs more useful to decision-makers.
    Baltussen R; Ament A; Leidl R
    Health Policy; 1996 Sep; 37(3):163-83. PubMed ID: 10160021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women.
    Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
    Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence.
    Campbell JD; McQueen RB; Briggs A
    Ann Am Thorac Soc; 2014 Feb; 11 Suppl 2():S105-11. PubMed ID: 24559022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008.
    Ismail Z; Peacock SJ; Kovacic L; Hoch JS
    Int J Technol Assess Health Care; 2017 Jan; 33(4):481-486. PubMed ID: 28871898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
    Hornberger J; Hirsch FR; Li Q; Page RD
    Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.